• Explore /
  • Poster
  • / TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring <em>ROS1</em> or <em>NTRK1-3</em> rearrangements.

TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements.

Abstract Video & Slides Poster

Authors

Robert Doebele

Robert Charles Doebele

University of Colorado, Aurora, CO

Robert Charles Doebele , Jessica Jiyeong Lin , Misako Nagasaka , Viola Weijia Zhu , Nashat Y. Gabrail , Lyudmila Bazhenova , Peter Meade Anderson , Benjamin J. Solomon , Arkadiusz Z. Dudek , Andrew William Pippas , Mihran Shirinian , Christina S Baik , Shanna Stopatschinskaja , D. Ross Camidge , Byoung Chul Cho , Alexander E. Drilon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03093116

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS9637)

DOI

10.1200/JCO.2020.38.15_suppl.TPS9637

Abstract #

TPS9637

Poster Bd #

403

Abstract Disclosures

Similar Posters

First Author: Jessica Jiyeong Lin

First Author: Misako Nagasaka

First Author: Mingfang Zhao

First Author: Alexander E. Drilon